X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
animals (11) 11
index medicus (9) 9
mice (8) 8
female (7) 7
oncology (7) 7
immunotherapy (6) 6
xenograft model antitumor assays (6) 6
cancer (5) 5
cell line, tumor (5) 5
tumors (5) 5
antibodies, monoclonal - pharmacology (4) 4
cd8 antigen (4) 4
lymphocytes t (4) 4
medicine, research & experimental (4) 4
mice, scid (4) 4
neoplasms - immunology (4) 4
tumor necrosis factor (4) 4
antibodies, monoclonal - immunology (3) 3
b7-h1 antigen - antagonists & inhibitors (3) 3
disease models, animal (3) 3
immunology (3) 3
immunomodulation (3) 3
ligands (3) 3
lymphocyte activation - drug effects (3) 3
lymphocytes (3) 3
mice, inbred c57bl (3) 3
ox40l protein (3) 3
proteins (3) 3
regulatory t-cells (3) 3
suppression (3) 3
t-lymphocytes - immunology (3) 3
toxicity (3) 3
transduction, genetic (3) 3
activation (2) 2
adenoviridae - genetics (2) 2
advanced melanoma (2) 2
animal models (2) 2
antibodies (2) 2
antibodies, bispecific - immunology (2) 2
antibody (2) 2
antibody-dependent cell cytotoxicity - drug effects (2) 2
anticancer properties (2) 2
antitumor activity (2) 2
antitumor efficacy (2) 2
article (2) 2
b7-h1 antigen - metabolism (2) 2
biotechnology & applied microbiology (2) 2
bispecific antibody (2) 2
cancer-immunotherapy (2) 2
carcinoembryonic antigen (2) 2
carcinoembryonic antigen - immunology (2) 2
cd3 complex - immunology (2) 2
cd4 antigen (2) 2
cd8-positive t-lymphocytes - immunology (2) 2
cea (2) 2
cell line (2) 2
cell proliferation (2) 2
cells (2) 2
cells, cultured (2) 2
cetuximab (2) 2
cho cells (2) 2
colorectal neoplasms - drug therapy (2) 2
coxsackie and adenovirus receptor-like membrane protein (2) 2
cricetinae (2) 2
cricetulus (2) 2
cytokines (2) 2
cytotoxicity (2) 2
cytotoxicity, immunologic - drug effects (2) 2
cytotoxicity, immunologic - immunology (2) 2
effector (2) 2
fusion protein (2) 2
genetics & heredity (2) 2
growth-factor receptor (2) 2
hela cells (2) 2
immune checkpoint (2) 2
immunity (2) 2
immunoglobulin fc fragments - immunology (2) 2
lymphocyte activation - immunology (2) 2
male (2) 2
memory cells (2) 2
mice, inbred nod (2) 2
mice, nude (2) 2
monoclonal-antibody (2) 2
mutation (2) 2
neoplasms - drug therapy (2) 2
neoplasms - genetics (2) 2
neoplasms - pathology (2) 2
neoplasms - therapy (2) 2
oligopeptides - genetics (2) 2
oligopeptides - metabolism (2) 2
ovarian-cancer (2) 2
pd-1 protein (2) 2
pd-l1 protein (2) 2
programmed cell death 1 receptor - antagonists & inhibitors (2) 2
receptors, ox40 - agonists (2) 2
receptors, virus - metabolism (2) 2
recombinant fusion proteins - immunology (2) 2
t-lymphocyte subsets - immunology (2) 2
t-lymphocyte subsets - metabolism (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 4902 - 4902
GITR is a member of the TNFR superfamily of proteins and is expressed on resting regulatory T-cells and on other T-cells following activation. Signals through... 
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2006, Volume 5, Issue 12, pp. 3122 - 3129
The humanized monoclonal antibody Abegrin™, currently in phase II trials for treatment of solid tumors, specifically recognizes the integrin α v β 3 . Due to... 
Tumor | Integrin | Abegrin | Antibody | ADCC
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 13, pp. 3416 - 3427
Purpose: To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency and the potential to agonize the GITR... 
EFFECTOR | RESPONSES | ACTIVATION | FC-GAMMA RECEPTORS | ONCOLOGY | IN-VIVO | REGULATORY T-CELLS | CANCER-IMMUNOTHERAPY | SUPPRESSION | TNF | TUMOR-IMMUNITY | Tumor Necrosis Factors - agonists | Tumor Necrosis Factors - genetics | Humans | Melanoma, Experimental - therapy | Membrane Glycoproteins - agonists | Glucocorticoid-Induced TNFR-Related Protein - administration & dosage | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Oncogene Proteins, Fusion - administration & dosage | CTLA-4 Antigen - immunology | Tumor Necrosis Factors - immunology | B7-H1 Antigen - immunology | Oncogene Proteins, Fusion - immunology | Animals | B7-H1 Antigen - antagonists & inhibitors | Melanoma, Experimental - genetics | Melanoma, Experimental - immunology | CD8-Positive T-Lymphocytes - drug effects | Glucocorticoid-Induced TNFR-Related Protein - immunology | Mice | Membrane Glycoproteins - immunology | Programmed Cell Death 1 Receptor - immunology | CD8-Positive T-Lymphocytes - immunology | CTLA-4 Antigen - antagonists & inhibitors | Disease Models, Animal | Cell proliferation | Animal models | PD-1 protein | CD8 antigen | Antibodies | Antagonists | Lymphocytes T | Immunity | Anticancer properties | Proteins | CTLA-4 protein | Lymphocytes | Immunotherapy | Fusion protein | Valency | CD4 antigen | Ox40L protein | Immune checkpoint | Experimental design | Tumor necrosis factor | PD-L1 protein | Antitumor activity | Ligands | Cancer | Tumors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2006, Volume 5, Issue 12, pp. 3122 - 3129
The humanized monoclonal antibody Abegrin super(TM), currently in phase II trials for treatment of solid tumors, specifically recognizes the integrin alpha... 
Journal Article
Edmonton Journal, 01/1992
The next night, Monday, [Joel] and [Jon] spent the night at the hospital with [Kathy]. Jon and Kathy were climbing the walls, their bodies screaming for the... 
Newspaper Article
Scientific Reports, ISSN 2045-2322, 01/2017, Volume 7, Issue 1, pp. 40098 - 40098
Journal Article
Molecular Therapy, ISSN 1525-0016, 08/2017, Volume 25, Issue 8, pp. 1917 - 1932
Vesicular stomatitis virus encoding the IFNβ transgene (VSV-IFNβ) is a mediator of potent oncolytic activity and is undergoing clinical evaluation for the... 
VSV | agonist | oncolytic virus | immune-oncology | checkpoint inhibitor | MEDICINE, RESEARCH & EXPERIMENTAL | PD-1 BLOCKADE | INTERFERON-BETA | LUNG-CANCER | MULTIPLE-SCLEROSIS | ADVANCED MELANOMA | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | REGULATORY T-CELLS | MYELOID-LEUKEMIA | VESICULAR STOMATITIS-VIRUS | TUMOR MICROENVIRONMENT | ANTITUMOR EFFICACY | T-Lymphocyte Subsets - immunology | Immunotherapy - methods | Receptors, OX40 - agonists | Humans | Biomarkers, Tumor | Neoplasms - therapy | Tumor Microenvironment - genetics | Melanoma, Experimental | Neoplasms - genetics | Interferon-beta - genetics | Interferons - genetics | Transgenes | Disease Models, Animal | Gene Expression | Transduction, Genetic | Vesicular stomatitis Indiana virus - genetics | Immunomodulation | Antibodies, Monoclonal - pharmacology | Oncolytic Viruses - genetics | Combined Modality Therapy | Genetic Vectors - genetics | Oncolytic Virotherapy | Tumor Microenvironment - immunology | Xenograft Model Antitumor Assays | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - antagonists & inhibitors | Interferon-beta - metabolism | Virus Replication | Neoplasms - immunology | T-Lymphocyte Subsets - metabolism | Interferons - metabolism | Mice | Neoplasms - pathology | Genetic Therapy - methods | Antigens | Cytokines | Peptides | Immunoregulation | β-Interferon | CD8 antigen | Viruses | Infections | Lymphocytes T | Experiments | Stomatitis | Immune checkpoint | Tumor necrosis factor | Antigen (tumor-associated) | Oncolysis | Solid tumors | Viral infections | Cancer | Tumors | Original
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2686 - 2698
Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune system. In... 
IMMUNOGENICITY | ACTIVATION | DENDRITIC CELLS | ONCOLOGY | DEATH | COMBINATION | SUPPRESSION | T-CELLS | IPILIMUMAB | CANCER IMMUNOTHERAPIES | ANTITUMOR EFFICACY | T-Lymphocyte Subsets - immunology | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Immunoconjugates - pharmacology | T-Lymphocyte Subsets - drug effects | Cancer Vaccines | Immunotherapy | Female | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Antibodies, Monoclonal - immunology | Disease Models, Animal | Benzodiazepines - pharmacology | Rats | Immunophenotyping | Lymphocytes, Tumor-Infiltrating - drug effects | Drug Synergism | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | T-Lymphocyte Subsets - metabolism | Biomarkers | Cell Line, Tumor | Immunologic Memory | Mice | Immunologic Factors - pharmacology | Lymphocytes, Tumor-Infiltrating - immunology | Drugs | Conjugates | Animal models | PD-1 protein | Toxicity | CD8 antigen | Antibodies | Cytotoxicity | Oncology | Lymphocytes T | Synergism | Immunosuppressive agents | Anticancer properties | Proteins | Lymphocytes | Immune system | Memory cells | Myeloid cells | Immune response | Immunomodulation | Tumor cells | Immunodeficiency | Ox40L protein | Immunogenicity | Tumor necrosis factor | Cell death | PD-L1 protein | Ligands | Antitumor activity | Combinatorial analysis | Tumors | Apoptosis | Cancer | Payloads | Index Medicus
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2018, Volume 17, Issue 5, pp. 1024 - 1038
Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector... 
EFFECTOR | ONCOLOGY | BLOCKS | EXPANSION | REGULATORY T-CELLS | COSTIMULATION | SUPPRESSION | CD134 | CUTTING EDGE | Recombinant Fusion Proteins - immunology | T-Lymphocytes, Regulatory - metabolism | Receptors, OX40 - agonists | OX40 Ligand - genetics | Recombinant Fusion Proteins - pharmacology | Immunoglobulin Fc Fragments - metabolism | OX40 Ligand - metabolism | Humans | Protein Multimerization - immunology | Macaca mulatta | Receptors, OX40 - immunology | T-Lymphocytes, Regulatory - immunology | Lymphocyte Activation - immunology | Receptors, OX40 - metabolism | Immunoglobulin Fc Fragments - immunology | T-Lymphocytes - metabolism | Immunoglobulin G - immunology | HEK293 Cells | Female | Cytotoxicity, Immunologic - drug effects | Cytokines - immunology | Cytokines - metabolism | Recombinant Fusion Proteins - chemistry | Animals | Immunoglobulin G - genetics | OX40 Ligand - immunology | Lymphocyte Activation - drug effects | Cell Line, Tumor | T-Lymphocytes - immunology | Cytotoxicity, Immunologic - immunology | Immunoglobulin Fc Fragments - genetics | Immunoglobulin G - metabolism | Cytolytic activity | Cell proliferation | Toxicity | CD8 antigen | Cytotoxicity | Lymphocytes T | Immunity | Proteins | Receptors | Cell growth | Lymphocytes | Peripheral blood | Primates | CD25 antigen | Fusion protein | Recombinant | Immunological memory | Memory cells | Cell survival | Cytokines | Immunomodulation | T cell receptors | CD134 antigen | CD4 antigen | Fc receptors | Ox40L protein | Lymphocytes B | Tumor necrosis factor | Ligands | Cancer | Tumors | OX40 | fusion protein | OX40 ligand | MEDI6383 | immunotherapy
Journal Article
OncoImmunology, ISSN 2162-4011, 08/2016, Volume 5, Issue 8, p. e1208875
MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447... 
Adenosine | CD73 | MEDI9447 | syngeneic tumor model | tumor microenvironment | monoclonal antibody | MOLECULE | ANTIBODY | CANCER-IMMUNOTHERAPY | IMMUNOLOGY | PROTECTS | ADHESION | T-CELL INFILTRATION | THERAPY | INHIBITION | MELANOMA | ONCOLOGY
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 285 - 285
Journal Article
mAbs, ISSN 1942-0862, 11/2014, Volume 6, Issue 6, pp. 1571 - 1584
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. 3056 - 3056
Journal Article
Neoplasia, ISSN 1476-5586, 06/2009, Volume 11, Issue 6, pp. 509,IN1 - 517,IN2
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.